Be-Qualms
A Multicenter observational Belgian study assessing the impact of newly started treatment on the QOL in patients suffering from myelodysplastic syndromes.
Inclusion Criteria
- Adult patients with a new diagnosis of MDS (according to WHO 2016 definitions (3) or known patients with MDS who are about to start a new treatment.
- Signed informed consent.
- Patients enrolled in an unblinded interventional therapeutic trial are eligible.
-
Exclusion Criteria
- Patients with acute leukemia defined as >20% bone marrow blasts.
- Patients suffering from an overlap syndrome myelodysplastic/myeloproliferative disease.
- Patients in post allogeneic transplant setting.
- Patients enrolled in a blinded interventional therapeutic trial.
- Patients starting with multiple treatments under investigation at the same moment apart from intensive chemotherapy.
- Newly diagnosed patients who do not start with treatment.
- Patients who started a previous treatment less then 12 weeks ago apart from packed cell transfusion (up to 4 weeks allowed).
- Diagnosis of any previous or concomitant malignancy except when the patient successfully completed treatment (chemotherapy and/or surgery and/or radiotherapy) with curative intent for this malignancy at least 3 months prior to inclusion.
Patients refusing to sign informed consent.
Participating sites
- ZNA
- Imelda
- AZ KLINA
- Sint Dimpna Geel
- Heilig Hart Lier
- UZA
- CH Jolimont
- CHR Mons Hainaut
- CHU Ambroise Paré
- CHU - UCL Namur site Godinne
- UZ Gent
- AZ Nikolaas
- Institut Jules Bordet
- UZ Brussel
- University Hospital Leuven Gasthuisberg
- CU Saint-Luc
- AZ Sint-Jan Brugge
- AZ Damiaan Oostende
- Gasthuiszusters Antwerpen
- CHR Namur
- BR Clinic Saint Pierre Ottignies